Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.
This report aims to provide a comprehensive presentation of the global market for Dendritic Cell Cancer Vaccine Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dendritic Cell Cancer Vaccine Immunotherapy. This report contains market size and forecasts of Dendritic Cell Cancer Vaccine Immunotherapy in global, including the following market information:
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Dendritic Cell Cancer Vaccine Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Provenge Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Dendritic Cell Cancer Vaccine Immunotherapy include Lineage Cell Therapeutics, AVAX Technologies, DCPrime, Gradalis, Heat Biologics, ImmunoCellular Therapeutics, Immunicum, MolecuVax and Northwest Biotherapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Dendritic Cell Cancer Vaccine Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dendritic Cell Cancer Vaccine Immunotherapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Segment Percentages, by Type, 2022 (%)
Provenge
Apceden
CreaVax
Others
Global Dendritic Cell Cancer Vaccine Immunotherapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Segment Percentages, by Application, 2022 (%)
Pediatrics
Adults
Global Dendritic Cell Cancer Vaccine Immunotherapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Dendritic Cell Cancer Vaccine Immunotherapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Dendritic Cell Cancer Vaccine Immunotherapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lineage Cell Therapeutics
AVAX Technologies
DCPrime
Gradalis
Heat Biologics
ImmunoCellular Therapeutics
Immunicum
MolecuVax
Northwest Biotherapeutics
Pique Therapeutics
Regeneus
Tessa Therapeutics
Vaccinogen
XEME Biopharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Dendritic Cell Cancer Vaccine Immunotherapy, market overview.
Chapter 2: Global Dendritic Cell Cancer Vaccine Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Dendritic Cell Cancer Vaccine Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dendritic Cell Cancer Vaccine Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Dendritic Cell Cancer Vaccine Immunotherapy Overall Market Size
2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size: 2022 VS 2030
2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Dendritic Cell Cancer Vaccine Immunotherapy Players in Global Market
3.2 Top Global Dendritic Cell Cancer Vaccine Immunotherapy Companies Ranked by Revenue
3.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Dendritic Cell Cancer Vaccine Immunotherapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Dendritic Cell Cancer Vaccine Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Dendritic Cell Cancer Vaccine Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 Dendritic Cell Cancer Vaccine Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Dendritic Cell Cancer Vaccine Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Markets, 2022 & 2030
4.1.2 Provenge
4.1.3 Apceden
4.1.4 CreaVax
4.1.5 Others
4.2 By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2024-2030
4.2.3 By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2022 & 2030
5.1.2 Pediatrics
5.1.3 Adults
5.2 By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2024-2030
5.2.3 By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2022 & 2030
6.2 By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2024-2030
6.2.3 By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2030
6.3.2 US Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.3.3 Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.3.4 Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2030
6.4.2 Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.4.3 France Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.4.4 U.K. Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.4.5 Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.4.6 Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.4.7 Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.4.8 Benelux Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2030
6.5.2 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.5.3 Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.5.4 South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.5.5 Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.5.6 India Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2030
6.6.2 Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.6.3 Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2030
6.7.2 Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.7.3 Israel Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.7.4 Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
6.7.5 UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Size, 2018-2030
7 Dendritic Cell Cancer Vaccine Immunotherapy Companies Profiles
7.1 Lineage Cell Therapeutics
7.1.1 Lineage Cell Therapeutics Company Summary
7.1.2 Lineage Cell Therapeutics Business Overview
7.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.1.4 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.1.5 Lineage Cell Therapeutics Key News & Latest Developments
7.2 AVAX Technologies
7.2.1 AVAX Technologies Company Summary
7.2.2 AVAX Technologies Business Overview
7.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.2.4 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.2.5 AVAX Technologies Key News & Latest Developments
7.3 DCPrime
7.3.1 DCPrime Company Summary
7.3.2 DCPrime Business Overview
7.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.3.4 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.3.5 DCPrime Key News & Latest Developments
7.4 Gradalis
7.4.1 Gradalis Company Summary
7.4.2 Gradalis Business Overview
7.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.4.4 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.4.5 Gradalis Key News & Latest Developments
7.5 Heat Biologics
7.5.1 Heat Biologics Company Summary
7.5.2 Heat Biologics Business Overview
7.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.5.4 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.5.5 Heat Biologics Key News & Latest Developments
7.6 ImmunoCellular Therapeutics
7.6.1 ImmunoCellular Therapeutics Company Summary
7.6.2 ImmunoCellular Therapeutics Business Overview
7.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.6.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.6.5 ImmunoCellular Therapeutics Key News & Latest Developments
7.7 Immunicum
7.7.1 Immunicum Company Summary
7.7.2 Immunicum Business Overview
7.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.7.4 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.7.5 Immunicum Key News & Latest Developments
7.8 MolecuVax
7.8.1 MolecuVax Company Summary
7.8.2 MolecuVax Business Overview
7.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.8.4 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.8.5 MolecuVax Key News & Latest Developments
7.9 Northwest Biotherapeutics
7.9.1 Northwest Biotherapeutics Company Summary
7.9.2 Northwest Biotherapeutics Business Overview
7.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.9.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.9.5 Northwest Biotherapeutics Key News & Latest Developments
7.10 Pique Therapeutics
7.10.1 Pique Therapeutics Company Summary
7.10.2 Pique Therapeutics Business Overview
7.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.10.4 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.10.5 Pique Therapeutics Key News & Latest Developments
7.11 Regeneus
7.11.1 Regeneus Company Summary
7.11.2 Regeneus Business Overview
7.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.11.4 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.11.5 Regeneus Key News & Latest Developments
7.12 Tessa Therapeutics
7.12.1 Tessa Therapeutics Company Summary
7.12.2 Tessa Therapeutics Business Overview
7.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.12.4 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.12.5 Tessa Therapeutics Key News & Latest Developments
7.13 Vaccinogen
7.13.1 Vaccinogen Company Summary
7.13.2 Vaccinogen Business Overview
7.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.13.4 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.13.5 Vaccinogen Key News & Latest Developments
7.14 XEME Biopharma
7.14.1 XEME Biopharma Company Summary
7.14.2 XEME Biopharma Business Overview
7.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Major Product Offerings
7.14.4 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global Market (2018-2023)
7.14.5 XEME Biopharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Dendritic Cell Cancer Vaccine Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers in Global Market
Table 3. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Dendritic Cell Cancer Vaccine Immunotherapy in Global Market
Table 5. Top Dendritic Cell Cancer Vaccine Immunotherapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Dendritic Cell Cancer Vaccine Immunotherapy Product Type
Table 9. List of Global Tier 1 Dendritic Cell Cancer Vaccine Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Dendritic Cell Cancer Vaccine Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Dendritic Cell Cancer Vaccine Immunotherapy Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 30. Lineage Cell Therapeutics Company Summary
Table 31. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 32. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 33. Lineage Cell Therapeutics Key News & Latest Developments
Table 34. AVAX Technologies Company Summary
Table 35. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 36. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 37. AVAX Technologies Key News & Latest Developments
Table 38. DCPrime Company Summary
Table 39. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 40. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 41. DCPrime Key News & Latest Developments
Table 42. Gradalis Company Summary
Table 43. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 44. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 45. Gradalis Key News & Latest Developments
Table 46. Heat Biologics Company Summary
Table 47. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 48. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 49. Heat Biologics Key News & Latest Developments
Table 50. ImmunoCellular Therapeutics Company Summary
Table 51. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 52. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 53. ImmunoCellular Therapeutics Key News & Latest Developments
Table 54. Immunicum Company Summary
Table 55. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 56. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 57. Immunicum Key News & Latest Developments
Table 58. MolecuVax Company Summary
Table 59. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 60. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 61. MolecuVax Key News & Latest Developments
Table 62. Northwest Biotherapeutics Company Summary
Table 63. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 64. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 65. Northwest Biotherapeutics Key News & Latest Developments
Table 66. Pique Therapeutics Company Summary
Table 67. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 68. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 69. Pique Therapeutics Key News & Latest Developments
Table 70. Regeneus Company Summary
Table 71. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 72. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 73. Regeneus Key News & Latest Developments
Table 74. Tessa Therapeutics Company Summary
Table 75. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 76. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 77. Tessa Therapeutics Key News & Latest Developments
Table 78. Vaccinogen Company Summary
Table 79. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 80. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 81. Vaccinogen Key News & Latest Developments
Table 82. XEME Biopharma Company Summary
Table 83. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product Offerings
Table 84. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 85. XEME Biopharma Key News & Latest Developments
List of Figures
Figure 1. Dendritic Cell Cancer Vaccine Immunotherapy Segment by Type in 2022
Figure 2. Dendritic Cell Cancer Vaccine Immunotherapy Segment by Application in 2022
Figure 3. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022
Figure 8. By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 10. By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 12. By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 14. By Region - Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 15. By Country - North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 16. US Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 20. Germany Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 21. France Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 28. China Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 32. India Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 34. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share, 2018-2030
Figure 37. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 41. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
